Neutropenic fever 200 mg IV q12h x2d, then 200 mg IV q24h

Aspergillosis, blastomycosis, histoplasmosis 200 mg IV q12h x2d, then 200 mg IV q24h

Aspergillosis 200 mg PO q12-24h

Blastomycosis, histoplasmosis 200 mg PO q24h

Toenail onychomycosis 200 mg PO q24h x12w

Fingernail onychomycosis 200 mg PO q12h x1w or 400 mg PO q24h x1w

Oral solution 1 mL = Itraconazole 10 mg

Oropharyngeal candidiasis 100 mg PO q12h x1~2w

Oropharyngeal candidiasis refractroy to fluconazole 100 mg PO q12h x2-4w

Esophageal candidiasis 100 mg PO q12h x≥3w

Capsules and oral solution are not interchangeable dose forms

Safety and efficacy in pediatric patients have not been established

CrCl >80CrCl 3-80CrCl <30Recommended dose IV q24hRecommended dose IV q24h with cautionAvoid

No data

General Information

  • Aspergillosis, invasive

  • Blastomycosis

  • Candidiasis of the esophagus

  • Candidiasis of the esophagus - HIV infection

  • Histoplasmosis, disseminated

  • HIV infection - oropharyngeal candidiasis

  • Onychomycosis due to dermatophyte

  • Oropharyngeal candidiasis

  • Pulmonary histoplasmosis

Black Box Warning: Itraconazole can cause or exacerbate congestive heart failure (CHF). Itraconazole oral capsules and tablets should not be administered for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as congestive heart failure (CHF).

Monitor liver function tests; signs and symptoms of peripheral neuropathy.

Evaluate signs and symptoms of congestive heart failure (CHF), especially in patients with preexisting risk factors.

Obtain fungal cultures prior to initiation.


  • Edema

  • Hypertension

  • Pruritus

  • Rash

  • GI upset

  • Dizziness

  • Headache

  • Rhinitis

  • Sinusitis

  • Upper respiratory infection

  • Fatigue

  • Fever


  • Congestive heart failure

  • Pancreatitis

  • Hepatotoxicity

  • Anaphylaxis

  • Peripheral nerve disease

  • Hearing loss

  • Pulmonary edema


  • CYP3A4 inducers and inhibitors

  • CYP2D6 inhibitors

  • Ergot alkaloids

  • QT interval prolonging drugs

Multiple drug-drug interactions

Antimicrobial class: Antifungal, Triazole

Pregnancy category: C

Average serum half life: 16-28 hours (single dose), 34-42 hours (repeated dosing)

Precautions: Discontinuation may be warranted if increased risk of CHF with ischemic and valvular disease, pulmonary disease, renal failure, or edematous disorders.

Not recommended in patients with hepatic impairment and those at risk of systemic candidiasis.

Discontinue use if neuropathy or hepatotoxicity occurs.

Avoid use in geriatric patients unless benefit outweighs risk.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.